TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37906216

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitor (CGM; Medtronic Guardian)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Physical activity sensors (activity bracelet - Garmin Vivosmart 3, hip-worn sensor - UKK Exsed, electrocardiography sensor - Firstbeat 2)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Unified Theory of Acceptance and Use of Technology (UTAUT) questionnaire
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Mobile app combining glucose, nutrition, and physical activity data
Number of subjects: 10
Study: 37906406

Group type: EXPERIMENTAL
Intervention: Less neurotoxic regimen consisting of darunavir/cobicistat plus emtricitabine plus maraviroc
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maintaining actual care (control group)
Number of subjects: 0
Study: 37906417

Group type: EXPERIMENTAL
Intervention: Guselkumab (100 mg subcutaneous injections at Week 0, Week 4, then every 8 weeks in psoriasis; every 4 weeks or every 8 weeks in PsA)
Number of subjects: 4399

Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 4399
Study: 37906649

Group type: EXPERIMENTAL
Intervention: Abemaciclib + Trastuzumab + Fulvestrant (Arm A)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Abemaciclib + Trastuzumab (Arm B)
Number of subjects: 237

Group type: COMPARATOR
Intervention: SOC Chemotherapy + Trastuzumab (Arm C)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Luminal subtypes (exploratory analysis)
Number of subjects: 237
Study: 37906724

Group type: EXPERIMENTAL
Intervention: CRS + HIPEC (CRS + H)
Number of subjects: 105

Group type: COMPARATOR
Intervention: CRS alone (CRS-A)
Number of subjects: 105
Study: 37906726

Group type: EXPERIMENTAL
Intervention: Ofranergene obadenovec (ofra-vec) with weekly paclitaxel
Number of subjects: 409

Group type: COMPARATOR
Intervention: Placebo with weekly paclitaxel
Number of subjects: 409
Study: 37907210

Group type: EXPERIMENTAL
Intervention: pyrotinib (400 mg once daily) combined with trastuzumab (8 mg/kg in cycle 1 and 6 mg/kg in subsequent cycles) and docetaxel (75 mg/m2)
Number of subjects: 590

Group type: COMPARATOR
Intervention: placebo combined with trastuzumab (8 mg/kg in cycle 1 and 6 mg/kg in subsequent cycles) and docetaxel (75 mg/m2)
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: pyrotinib (400 mg once daily)
Number of subjects: 590

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: pyrotinib, trastuzumab, and docetaxel
Number of subjects: 590

Group type: COMPARATOR
Intervention: placebo, trastuzumab, and docetaxel
Number of subjects: 590
Study: 37907221

Group type: EXPERIMENTAL
Intervention: NIZ985 (1 µg/kg TIW)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: NIZ985 (1 µg/kg TIW) + spartalizumab (400 mg Q4W)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: NIZ985 (single-agent)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: NIZ985 + spartalizumab
Number of subjects: 83
Study: 37907305

Group type: EXPERIMENTAL
Intervention: Tinzaparin lead-in followed by rivaroxaban
Number of subjects: 60

Group type: COMPARATOR
Intervention: Rivaroxaban alone
Number of subjects: 60
Study: 37907448

Group type: EXPERIMENTAL
Intervention: Occupational heat stress recommendation compliance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Work-rest ratio-matched positive control scenario
Number of subjects: 0
Study: 37907482

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT)
Number of subjects: 1348

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (i.v. thrombolysis)
Number of subjects: 1348

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1348

Group type: EXPERIMENTAL
Intervention: Pre-stroke modified Rankin scale (mRS)
Number of subjects: 1348

Group type: EXPERIMENTAL
Intervention: Baseline NIHSS
Number of subjects: 1348

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 1348

Group type: EXPERIMENTAL
Intervention: Number of passes during thrombectomy
Number of subjects: 1348

Group type: EXPERIMENTAL
Intervention: Intracranial hemorrhage
Number of subjects: 1348

Group type: EXPERIMENTAL
Intervention: Dissections, perforations
Number of subjects: 1348

Group type: EXPERIMENTAL
Intervention: Clot migration, embolization
Number of subjects: 1348
Study: 37907503

Group type: EXPERIMENTAL
Intervention: Intra-articular injection of Immunity-and-matrix-regulatory cells (IMRCs)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Intra-articular injection of umbilical cord MSCs (as a comparison)
Number of subjects: 18
Study: 37907796

Group type: EXPERIMENTAL
Intervention: 60 mg/kg L-citrulline every 6 hours for 72 hours
Number of subjects: 6
Study: 37907858

Group type: EXPERIMENTAL
Intervention: Multilevel mobility intervention (information and exercise booklets, mobility diary, iPad with exercise videos, e-learning for healthcare professionals, oral presentation, mobility checklist, posters and pictures on the wards)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Multilevel mobility intervention
Number of subjects: 274

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 274
Study: 37907927

Group type: EXPERIMENTAL
Intervention: Needle tenotomy
Number of subjects: 244

Group type: COMPARATOR
Intervention: Blade tenotomy
Number of subjects: 244
Study: 37907990

Group type: EXPERIMENTAL
Intervention: Group-based pelvic floor muscle training (PFMT) delivered by a midwife
Number of subjects: 48

Group type: COMPARATOR
Intervention: Usual antenatal care (control group)
Number of subjects: 48
Study: 37908003

Group type: EXPERIMENTAL
Intervention: Recruitment strategies for patients with SMI
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Qualitative analysis of GP interviews
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Quantitative analysis of recruitment process
Number of subjects: 20
Study: 37908009

Group type: EXPERIMENTAL
Intervention: Vaginal birth after cesarean
Number of subjects: 8267

Group type: COMPARATOR
Intervention: Repeat cesarean birth
Number of subjects: 8267
Study: 37908016

Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 19

Group type: COMPARATOR
Intervention: Not applicable (no control group mentioned)
Number of subjects: 19
Study: 37908359

Group type: EXPERIMENTAL
Intervention: Dolutegravir/Lamivudine (DTG/3TC)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF)
Number of subjects: 66
Study: 37908441

Group type: EXPERIMENTAL
Intervention: Deep-learning methodology for CCTA analysis from co-registered NIRS-IVUS and CCTA data
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional CCTA expert analysis
Number of subjects: 70
Study: 37908549

Group type: EXPERIMENTAL
Intervention: Intermuscular adipose tissue (IMAT) measurements
Number of subjects: 1781

Group type: EXPERIMENTAL
Intervention: Perimuscular adipose tissue (PAT) measurements
Number of subjects: 1781
Study: 37908552

Group type: EXPERIMENTAL
Intervention: CCTA-derived fractional flow reserve (FFR)
Number of subjects: 4290

Group type: EXPERIMENTAL
Intervention: CCTA and CT-FFR findings
Number of subjects: 4290
Study: 37908625

Group type: EXPERIMENTAL
Intervention: MVP web-based intervention
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: MVP web-based intervention (women)
Number of subjects: 97
Study: 37909020

Group type: EXPERIMENTAL
Intervention: Pembrolizumab, FLOT, and trastuzumab
Number of subjects: 30
Study: 37909386

Group type: COMPARATOR
Intervention: tofacitinib (placebo-controlled trials)
Number of subjects: 330
Study: 37909532

Group type: EXPERIMENTAL
Intervention: Virtual reality glasses
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Mobile-assisted education
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control (routine care)
Number of subjects: 126
Study: 37909624

Group type: EXPERIMENTAL
Intervention: Polycystic ovary syndrome group (n=37)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (n=20)
Number of subjects: 57
Study: 37910105

Group type: EXPERIMENTAL
Intervention: SAAF intervention (7-session, 14 hours over 7 weeks)
Number of subjects: 472

Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 472
Study: 37910157

Group type: EXPERIMENTAL
Intervention: Goal2Quit mobile app intervention with a 2-week sample of combination nicotine replacement therapy (NRT)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Treatment as usual (self-help booklet for quitting smoking not tailored for depression)
Number of subjects: 150
Study: 37910166

Group type: EXPERIMENTAL
Intervention: BCAA supplementation (100 mg/kg body weight daily) with exercise (high-volume, moderate-intensity, whole-body exercise training 3 times per week for 8 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Exercise (high-volume, moderate-intensity, whole-body exercise training 3 times per week for 8 weeks)
Number of subjects: 30
Study: 37910313

Group type: EXPERIMENTAL
Intervention: Tenapanor (5 to 30 mg/dose, orally, twice-daily for 16 weeks)
Number of subjects: 54
Study: 37910335

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 0
Study: 37910523

Group type: EXPERIMENTAL
Intervention: Branded Enoxaparin (BE)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Biosimilar Enoxaparin (BSE)
Number of subjects: 168
Study: 37910603

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Observation period followed by delayed FMT if stool cultures were MDRO positive at day 36
Number of subjects: 11
Study: 37910805

Group type: EXPERIMENTAL
Intervention: Novel Patient-Reported Outcome Instrument
Number of subjects: 0
Study: 37910822

Group type: EXPERIMENTAL
Intervention: Pembrolizumab + Chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo + Chemotherapy
Number of subjects: 0
Study: 37913505

Group type: EXPERIMENTAL
Intervention: 100 mg thalidomide
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 50 mg thalidomide
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 37913676

Group type: EXPERIMENTAL
Intervention: Total number of steps
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Deep sleep proportion
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Median heart rate
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Proportion very active
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Total number of floors
Number of subjects: 31
Study: 37913818

Group type: EXPERIMENTAL
Intervention: Arnica + Standard Therapy (ST)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mucopolysaccharide Polysulfate (MPSP) + Standard Therapy (ST)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard Therapy (ST)
Number of subjects: 60
Study: 37913853

Group type: EXPERIMENTAL
Intervention: Apple Watch and iPhone used for routine ECG recording
Number of subjects: 1420
Study: 37913936

Group type: EXPERIMENTAL
Intervention: Neuromodulators as solo therapy
Number of subjects: 129

Group type: COMPARATOR
Intervention: Prokinetics as solo new therapy
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Prokinetics combined with gastroparesis diets or neuromodulators
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Neuromodulators as solo new therapy with nondelayed gastric emptying
Number of subjects: 129
Study: 37914086

Group type: EXPERIMENTAL
Intervention: Iptacopan (LNP023)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37914178

Group type: EXPERIMENTAL
Intervention: Healthy sleep duration (HSD; 9.5 hours in bed/night)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Restricted sleep (RS; 6.5 hours in bed/night)
Number of subjects: 31
Study: 37914392

Group type: EXPERIMENTAL
Intervention: WEB 17 device
Number of subjects: 163
Study: 37914482

Group type: EXPERIMENTAL
Intervention: Decitabine (20 mg/m²)
Number of subjects: 606

Group type: COMPARATOR
Intervention: 3+7 chemotherapy
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Decitabine
Number of subjects: 606
Study: 37914483

Group type: EXPERIMENTAL
Intervention: Cusatuzumab 10 mg/kg
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Cusatuzumab 20 mg/kg
Number of subjects: 103
Study: 37914581

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine sedation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propofol sedation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Natural sleep
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 0
Study: 37914594

Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg once daily for 5 years
Number of subjects: 0
Study: 37914804

Group type: EXPERIMENTAL
Intervention: LDL (low-density lipoproteins)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-apoB subjects
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: LDL-induced WAT IL-1β-secretion
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Adjustment for IL-1β-secretion
Number of subjects: 40
Study: 37914855

Group type: EXPERIMENTAL
Intervention: Neonates with ASDs
Number of subjects: 438

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 438
Study: 37914976

Group type: EXPERIMENTAL
Intervention: NYM016 (novel small-molecule PSMA-targeted fluorescence probe)
Number of subjects: 0
Study: 37914983

Group type: EXPERIMENTAL
Intervention: AZD7442 (tixagevimab/cilgavimab)
Number of subjects: 903

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 903
Study: 37915038

Group type: EXPERIMENTAL
Intervention: Intrathecal idursulfase-IT
Number of subjects: 47

Group type: COMPARATOR
Intervention: No intrathecal idursulfase-IT
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Intrathecal idursulfase-IT (children aged < 6 years)
Number of subjects: 47

Group type: COMPARATOR
Intervention: No intrathecal idursulfase-IT (children aged < 6 years)
Number of subjects: 47
Study: 37915337

Group type: EXPERIMENTAL
Intervention: Enhanced vitamin C serum (eVCS)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: eVCS and retinol-bakuchiol serum (RBS) combination
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: eVCS-RSB combination
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control
Number of subjects: 29
Study: 37915438

Group type: EXPERIMENTAL
Intervention: Mindfulness-based music therapy (MBMT)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Mindfulness intervention (MI)
Number of subjects: 92
Study: 37915546

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 100 mg bid + Selenium 100 mcg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Resveratrol 350 mg bid + TA-65 (Astragalus Membranaceus extract) 100U
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo-1 bid + Placebo-2
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Secondary variables (handgrip strength, aerobic capacity at the step test and quality of life)
Number of subjects: 120
Study: 37915619

Group type: EXPERIMENTAL
Intervention: Nutritional supplement containing zinc, vitamins B, calcium, iodine, iron, β-carotene, and folic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control supplement containing calcium, iodine, iron, β-carotene, and folic acid
Number of subjects: 0
Study: 37915911

Group type: EXPERIMENTAL
Intervention: 4-week supervised exercise intervention (two sessions per week for 4 weeks, totaling eight sessions)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 4-week supervised exercise intervention
Number of subjects: 34
Study: 37915938

Group type: EXPERIMENTAL
Intervention: HDx (expanded hemodialysis)
Number of subjects: 0

Group type: COMPARATOR
Intervention: OL-HDF (online hemodiafiltration)
Number of subjects: 0
Study: 37916028

Group type: EXPERIMENTAL
Intervention: Subcutaneous (s.c.) once-weekly semaglutide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37916030

Group type: EXPERIMENTAL
Intervention: Swank diet (low-saturated fat)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified Paleolithic elimination diet (Wahls)
Number of subjects: 0
Study: 37916266

Group type: EXPERIMENTAL
Intervention: MMBV test
Number of subjects: 736

Group type: COMPARATOR
Intervention: Physician's etiological suspicion
Number of subjects: 736
Study: 37916303

Group type: EXPERIMENTAL
Intervention: Axitinib 5 mg administered twice daily for 8 weeks
Number of subjects: 27
Study: 37916412

Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis (PD)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study: 37916517

Group type: EXPERIMENTAL
Intervention: Intensive treatment with SBP target <120 mmHg, TTR calculated based on SBP measurements during the first 3-month follow-up.
Number of subjects: 7965

Group type: COMPARATOR
Intervention: Standard treatment with SBP target <140 mmHg, TTR calculated based on SBP measurements during the first 3-month follow-up.
Number of subjects: 7965
Study: 37916620

Group type: EXPERIMENTAL
Intervention: Sibeprenlimab 2 mg/kg
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Sibeprenlimab 4 mg/kg
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Sibeprenlimab 8 mg/kg
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study: 37916745

Group type: COMPARATOR
Intervention: Antioxidant therapy
Number of subjects: 10468
Study: 37916843

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss (WW, WeightWatchers)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 61
Study: 37916926

Group type: EXPERIMENTAL
Intervention: taTME
Number of subjects: 1089

Group type: COMPARATOR
Intervention: laTME
Number of subjects: 1089

Group type: EXPERIMENTAL
Intervention: taTME and laTME
Number of subjects: 1089
Study: 37917058

Group type: EXPERIMENTAL
Intervention: Dostarlimab 500 mg intravenously every 3 weeks for 4 doses, then 1000 mg every 6 weeks until disease progression, discontinuation, or withdrawal.
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Dostarlimab treatment.
Number of subjects: 327
Study: 37917063

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Blood Pressure Reduction (MB-BP) program
Number of subjects: 201

Group type: COMPARATOR
Intervention: Enhanced usual care (control group)
Number of subjects: 201
Study: 37917111

Group type: EXPERIMENTAL
Intervention: Artificial Tears
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no artificial tears)
Number of subjects: 0
Study: 37917140

Group type: EXPERIMENTAL
Intervention: Twice-weekly outpatient rehabilitation intervention (weekly physical and occupational therapy for 11 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Twice-weekly outpatient rehabilitation intervention
Number of subjects: 0
Study: 37917146

Group type: EXPERIMENTAL
Intervention: Teen Well Check (n=61)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Assessment-only control (n=62)
Number of subjects: 123
Study: 37917187

Group type: EXPERIMENTAL
Intervention: Ivosidenib 500 mg daily in 28-day cycles
Number of subjects: 29
Study: 37917211

Group type: EXPERIMENTAL
Intervention: Intermittent Intrapulmonary Deflation (IID)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Positive Expiratory Pressure (PEP)
Number of subjects: 1
Study: 37917218

Group type: EXPERIMENTAL
Intervention: Bone targeted agents (BTAs)
Number of subjects: 881

Group type: COMPARATOR
Intervention: Pembrolizumab
Number of subjects: 881

Group type: COMPARATOR
Intervention: Radiation therapy
Number of subjects: 881
Study: 37917289

Group type: EXPERIMENTAL
Intervention: Ritlecitinib
Number of subjects: 12
Study: 37917417

Group type: EXPERIMENTAL
Intervention: Normal-weight obesity (NWO)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Metabolically healthy obesity (MHO)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy controls (CON)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Metabolically unhealthy obesity (MUO)
Number of subjects: 40
Study: 37917438

Group type: EXPERIMENTAL
Intervention: Symptom catastrophizing
Number of subjects: 0
Study: 37917638

Group type: EXPERIMENTAL
Intervention: Chronic undernutrition
Number of subjects: 918

Group type: EXPERIMENTAL
Intervention: Neurodevelopmental lag
Number of subjects: 918

Group type: EXPERIMENTAL
Intervention: At risk of neurodevelopmental delay
Number of subjects: 918

Group type: EXPERIMENTAL
Intervention: Co-occurrence of stunting and suboptimal neurodevelopment
Number of subjects: 918

Group type: EXPERIMENTAL
Intervention: Predictors of child development
Number of subjects: 918
Study: 37917826

Group type: EXPERIMENTAL
Intervention: levcromakalim (50 µg/mL)
Number of subjects: 21

Group type: COMPARATOR
Intervention: placebo (isotonic saline)
Number of subjects: 21
Study: 37917913

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37917943

Group type: EXPERIMENTAL
Intervention: 1 g intravenous calcium chloride
Number of subjects: 120

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 120
Study: 37918066

Group type: EXPERIMENTAL
Intervention: Behavioural intervention consisting of five activities
Number of subjects: 106

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 106
Study: 37918129

Group type: EXPERIMENTAL
Intervention: Cx611
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 37918404

Group type: EXPERIMENTAL
Intervention: DFMO (125-1,000 mg/m)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 37918417

Group type: EXPERIMENTAL
Intervention: Community-based approach (symptom-based tuberculosis screening by community health workers, TPT initiation by nurse in household, home visits for follow-up)
Number of subjects: 2894

Group type: EXPERIMENTAL
Intervention: Community-based approach
Number of subjects: 2894

Group type: COMPARATOR
Intervention: Standard-of-care facility-based approach (control group)
Number of subjects: 2894
Study: 37918674

Group type: EXPERIMENTAL
Intervention: Vitamin B supplementation (2 μg daily)
Number of subjects: 600
Study: 37918675

Group type: EXPERIMENTAL
Intervention: Salmon-containing Mediterranean-style diet
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (other 99 MED foods)
Number of subjects: 41
Study: 37918685

Group type: EXPERIMENTAL
Intervention: CADe (ENDO-AID)
Number of subjects: 766
Study: 37918790

Group type: EXPERIMENTAL
Intervention: BIS-guided anesthesia (target BIS values of 40-60)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Control group (sevoflurane dose determined by anaesthesiologist)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: BIS-guided anesthesia
Number of subjects: 163
Study: 37918855

Group type: EXPERIMENTAL
Intervention: Sovleplenib (oral Syk inhibitor)
Number of subjects: 0